GlaxoSmithKline (NYSE:GSK) had its price objective decreased by Argus to $40.00 in a research note issued to investors on Thursday. Argus currently has a buy rating on the pharmaceutical company’s stock.

A number of other equities analysts also recently commented on GSK. BidaskClub raised shares of GlaxoSmithKline from a strong sell rating to a sell rating in a report on Friday, August 25th. Morgan Stanley downgraded shares of GlaxoSmithKline from an equal weight rating to an underweight rating in a report on Friday, September 8th. J P Morgan Chase & Co reissued a neutral rating on shares of GlaxoSmithKline in a report on Thursday, September 14th. Zacks Investment Research raised shares of GlaxoSmithKline from a hold rating to a buy rating and set a $46.00 price target for the company in a report on Wednesday, October 18th. Finally, Bank of America downgraded shares of GlaxoSmithKline from a buy rating to a neutral rating in a report on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $39.71.

GlaxoSmithKline (NYSE GSK) traded up $0.26 during trading hours on Thursday, reaching $35.32. 5,393,594 shares of the company were exchanged, compared to its average volume of 3,484,149. GlaxoSmithKline has a 1-year low of $34.72 and a 1-year high of $44.53. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96. The firm has a market cap of $85,000.00, a price-to-earnings ratio of 12.74, a PEG ratio of 1.99 and a beta of 1.00.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Shareholders of record on Friday, November 10th will be given a $0.5037 dividend. This represents a $2.01 annualized dividend and a yield of 5.70%. The ex-dividend date of this dividend is Thursday, November 9th. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.49. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 154.26%.

In related news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the stock in a transaction on Monday, November 6th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 10.00% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of GSK. FinTrust Investment Advisory Services LLC acquired a new stake in shares of GlaxoSmithKline during the 3rd quarter worth approximately $401,000. Bingham Osborn & Scarborough LLC acquired a new stake in shares of GlaxoSmithKline during the 2nd quarter worth approximately $311,000. Freestone Capital Holdings LLC grew its position in shares of GlaxoSmithKline by 11.9% during the 2nd quarter. Freestone Capital Holdings LLC now owns 94,008 shares of the pharmaceutical company’s stock worth $4,054,000 after buying an additional 10,017 shares during the period. Renaissance Technologies LLC grew its position in shares of GlaxoSmithKline by 112.1% during the 2nd quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after buying an additional 4,935,900 shares during the period. Finally, Fulton Bank N.A. grew its position in shares of GlaxoSmithKline by 4.9% during the 3rd quarter. Fulton Bank N.A. now owns 75,269 shares of the pharmaceutical company’s stock worth $3,056,000 after buying an additional 3,515 shares during the period. Hedge funds and other institutional investors own 9.83% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.dailypolitical.com/2017/12/01/glaxosmithkline-gsk-given-new-40-00-price-target-at-argus.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.